Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis signs deal...

    Novartis signs deal with Gan & Lee as US government seeks to slash insulin cost

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-12-30T09:20:45+05:30  |  Updated On 16 Aug 2021 4:22 PM IST

    ZURICH: Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China's Gan & Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs.


    Novartis said on Wednesday its Sandoz generics unit is targeting Sanofi's Lantus (glargine), with about $6 billion in annual sales, Novo Nordisk's NovoLog (aspart) with about $3.2 billion, and Eli Lilly's Humalog (lispro), whose sales are some $2.9 billion.


    Sandoz will handle commercializing biosimilar, or near-copy, versions of these medicines around the world, while Gan & Lee will develop and manufacture them.


    Novartis's announcement comes after the U.S. Food and Drug Administration (FDA) announcement this month of changes meant to bring down insulin prices that have been escalating, crimping access and harming health.


    Additionally, Sanofi's efforts to protect Lantus patents were rejected last week by the United States Patent and Trademark Office, amid a challenge from generic drugmaker Mylan whose versions of Lantus under FDA review.


    "Sandoz has significant experience disrupting and transforming the healthcare landscape with off-patent medicines," Novartis said.


    "With a majority of insulin therapy offered by just a few companies, healthcare systems and the insulin supply are under increasing pressure to meet the growing demands."


    Gan & Lee, founded in 1998, focuses on insulin production and already makes versions of Lantus and Humalog, according to its website.


    The World Health Organisation estimates 400 million people worldwide have diabetes, a population seen expanding by more than a fifth by 2030 as people eat richer foods and have lifestyles that may put them at risk.


    Read Also: Novartis to buy France's CellforCure to boost cell, gene therapy
    diabetesFDAHealthcareHumaloginsulinLantusMylanNovartisNovo NordiskSandozU.S. Food and Drug AdministrationWHOWorld Health Organisation
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok